This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kyowa Hakko Kirin Co., Ltd
ClinicalTrials.gov Identifier:
NCT00857558
First received: March 4, 2009
Last updated: March 7, 2017
Last verified: March 2017
March 4, 2009
March 7, 2017
January 2009
March 2010   (Final data collection date for primary outcome measure)
changes in HbA1C from baseline [ Time Frame: 2w, 4w, 8w, 12w, 16w ]
Same as current
Complete list of historical versions of study NCT00857558 on ClinicalTrials.gov Archive Site
  • values and changes in HbA1c form baseline [ Time Frame: 2w, 4w, 8w, 12w, 16w ]
  • values and changes in fasting blood glucose (FSB) from baseline [ Time Frame: 2w, 4w, 8w, 12w, 16w ]
  • adverse event [ Time Frame: at any time ]
Same as current
Not Provided
Not Provided
 
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
A multicenter, randomized, double-blind, placebo-controlled, group-comparison study to investigate the safety and efficacy of OPC-262 in patients with type 2 diabetes
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Diabetes, Type 2
  • Drug: saxagliptin
    orally administration at 1 mg once a day for 12 weeks
  • Drug: saxagliptin
    orally administration at 2.5 mg once a day for 12 weeks
  • Drug: saxagliptin
    orally administration at 5 mg once a day for 12 weeks
  • Drug: placebo
    orally administration once a day for 12 weeks
  • Experimental: 1
    OPC-262 1mg
    Intervention: Drug: saxagliptin
  • Experimental: 2
    OPC-262 2.5mg
    Intervention: Drug: saxagliptin
  • Experimental: 3
    OPC-262 5mg
    Intervention: Drug: saxagliptin
  • Placebo Comparator: 4
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
350
May 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes patients with HbA1c above 7.0% and below 10%
  • Patients who are capable of giving informed consent
  • Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner

Exclusion Criteria:

  • Patients with type1 diabetes mellitus, patients with diabetes mellitus or impaired glucose tolerance (IGT) due to other specified mechanism or diseases, and patients with gestational diabetes mellitus
  • Patients with a medical history of diabetes coma
  • Patients with poorly-controlled hypertension
  • Patients with heart failure
  • Patients with a complication of active hepatitis or hepatic cirrhosis
  • Patients undergoing treatment of glomeruler diseases other than diabetic nephropathy
  • Patients with a history or complication of malignant tumor
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00857558
262-08-001
JapicCTI-090697 ( Other Identifier: JAPIC )
No
Not Provided
Not Provided
Not Provided
Kyowa Hakko Kirin Co., Ltd
Kyowa Hakko Kirin Co., Ltd
Not Provided
Study Director: Katsuhisa Saito OPC-J
Kyowa Hakko Kirin Co., Ltd
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP